M&A Spinn Off

Here are your up-to-date news results!
Clicking the title of the article will give you the original publication.
You can share an article quickly with colleagues via Twitter and LinkedIn!


Gatehouse Bio collaborates with AstraZeneca to accelerate new drug discovery
Published:

Gatehouse Bio’s ‘sRNAlytics platform’ identifies novel small RNA (sRNA) signatures and illuminates molecular pathways correlated to and potentially driving disease. “Our annotation library of over 1.4M small RNA

The post Gatehouse Bio collaborates with AstraZeneca to accelerate new drug discovery appeared first on Pharmaceutical Business review.

AWS announces strategic collaboration with Novartis to accelerate digital transformation of its business operations
Published:

This enterprise-wide data and analytics platform is expected to form the foundation for custom solutions powered by AWS AI and ML services to help drive agility, innovation, and

The post AWS announces strategic collaboration with Novartis to accelerate digital transformation of its business operations appeared first on Pharmaceutical Business review.

Bristol-Myers Squibb gets FDA breakthrough therapy status for Orencia to prevent GvHD
Published:

GvHD is a potentially life-threatening medical complication, which can affect patients receiving such transplants to treat certain genetic diseases and haematologic cancers. Orencia is an immunomodulator that disturbs

The post Bristol-Myers Squibb gets FDA breakthrough therapy status for Orencia to prevent GvHD appeared first on Pharmaceutical Business review.

Kodiak sells Baker Bros. royalty on net sales of KSI301
Published: 6 Dec 2019 | 0:40 UTC

Ophthalmic-focused Kodiak Sciences Inc. entered a royalty agreement with Baker Bros. Advisors involving Kodiak’s KSI301.

Venclose gets $27mm via Series C round
Published: 6 Dec 2019 | 0:40 UTC

Venclose Inc. raised $27mm in its Series C financing round led by Ally Bridge Group.

Amgen, Hummingbird Bio team up in potential $1.2bn multi-target collaboration
Published: 6 Dec 2019 | 0:40 UTC

Hummingbird Bioscience and Amgen Inc. are teaming up in a multi-target collaboration.

Inventiva launches with assets from Abbott subsidiary
Published: 6 Dec 2019 | 0:40 UTC

Inventiva Pharma has launched with assets from Laboratoires Fournier (part of Abbott’s Solvay). The assets include laboratories and equipment and a 230k molecule library.

Hummingbird Bio gets $19mm in Series B funding
Published: 6 Dec 2019 | 0:40 UTC

Four-year-old Hummingbird Bioscience raised $19mm through its Series B financing led by Mirae Asset Venture Investment and GNTech Venture Capital, which were joined by returning shareholders Heritas Capital and Seeds Capital, and first-time backers Delian Capital, Mirae Asset Capital, DAValue-GiltEdge, HB Investment, Wooshin Venture Investment, and Kiwoom Investment-Shinhan Capital.

Kodiak Sciences nets $259.4mm via FOPO
Published: 6 Dec 2019 | 0:40 UTC

Ophthalmic-focused Kodiak Sciences Inc. netted $295.4mm in a follow-on offering of 6mm common shares at $46 each. The company will use some of the funds to move its KSI301 towards the BLA filing in retinal vein occlusion and for sBLA submissions (expected in 2022) for wet age-related macular degeneration, diabetic macular edema (DME), and possibly diabetic retinopathy without DME. Additional funds will support development of additional pipeline candidates including KSI501 for DME and uveitis. Just one day prior to the offering, Kodiak sold Baker Bros. a capped 4.5% royalty on net sales of KSI301 in exchange for $225mm.

Hanmi gets rights to RAPT's CCR4 antagonist for cancer
Published: 5 Dec 2019 | 5:40 UTC

RAPT Therapeutics Inc. granted Hanmi Pharmaceutical Co. Ltd. exclusive rights to co-develop and sell the CCR4 antagonist FLX475 in South Korea, China, Taiwan, and Hong Kong.

Series D brings in $80.25mm for Impulse Dynamics
Published: 5 Dec 2019 | 0:40 UTC

Cardiovascular device maker Impulse Dynamics raised $80.25mm in its Series D financing led by Amzak Health Investors, which was joined by other first-time backers Wellington Management, Kennedy Lewis Investment Management, Acorn Biosciences, Minth Holdings, Zoll Medical, Abiomed, an undisclosed corporate investor, and Impulse Dynamics’ CEO and CFO. The company will use the proceeds for US commercialization of its Optimizer implantable smart system, which uses cardiac contractility modulation (CCM) technology to treat chronic heart failure.

Centene and WellCare Receive State Approvals for Pending Merger from Illinois and New Jersey
Published: 5 Dec 2019 | 0:00 UTC

All 27 States Have Provided Approvals of Centene's Control of WellCare Domestic Insurers

Movement Industries Corp. (OTC: MVNT) Completes Acquisition of SGX Industrial LLC
Published: 5 Dec 2019 | 0:00 UTC

Movement Industries Corp. (OTC PINK: MVNT) announced today that the company has completed the acquisition of SGX Industrial LLC.

Sartorius Acquires a Majority Stake in Cell Culture Media Specialist Biological Industries
Published: 5 Dec 2019 | 0:00 UTC

The transaction is subject to customary closing conditions and expected to be finalized by mid-December.

Astellas pays $3bn in cash for Audentes
Published: 4 Dec 2019 | 0:40 UTC

Astellas Pharma Inc. is paying $60 per share (a 112% premium) in cash to acquire seven-year-old gene therapy firm Audentes Therapeutics Inc. The deal has a total equity value of $3bn.

Retail Giants Sue Bausch and Others Over Glumetza
Published: 4 Dec 2019 | 0:32 UTC

Walgreens and other big name retailers have filed an antitrust suit against Bausch Health, its subsidiaries, and generic drugmaker Lupin for allegedly plotting to hike the price of Bausch’s diabetes drug Glumetza and Lupin’s generic version.

Asahi Kasei offers to buy Veloxis
Published: 28 Nov 2019 | 5:40 UTC

Asahi Kasei Corp. has offered to pay $0.88 (DKK6.00 each; a 5% premium) for publicly traded Veloxis Pharmaceuticals AS. The deal is valued at $1.31bn.

Novartis to acquire The Medicines Co. for $9.7bn
Published: 27 Nov 2019 | 5:40 UTC

Novartis AG agreed to acquire atherosclerotic cardiovascular disease (ASCVD)-focused public US biotech The Medicines Co. (TMC) in an all-cash transaction with a fully diluted equity value of $9.7bn. Approved by both boards, the deal is expected to close in Q1 2020.

Organogensis completes FOPO; nets $42.4mm
Published: 26 Nov 2019 | 5:40 UTC

Organogenesis Holdings Inc. netted $42.4mm through the public offering of 9mm common shares at $5. The company is developing biomaterials for the advanced wound care and surgical and sports markets, and will use the proceeds for continued product development, manufacturing, and commercialization support.

Rare disease diagnostics firm Centogene completes $52mm IPO on Nasdaq
Published: 26 Nov 2019 | 5:40 UTC

German biotech Centogene BV (rare disease diagnostics and biomarker discovery) netted $52mm in its initial public offering on Nasdaq of 4mm shares at $14, the low end of its anticipated $14-16 range.

Novartis Boosts Heart Treatment Portfolio with $9.7 Billion Deal
Published: 25 Nov 2019 | 23:35 UTC

Novartis has forged a merger agreement with The Medicines Company under which it will buy up the firm’s cholesterol drug inclisiran for a whopping $9.7 billion.

Dare acquires Microchips to enhance contraceptive offerings
Published: 22 Nov 2019 | 5:40 UTC

Dare Bioscience Inc. acquired private Microchips Biotech Inc. (wireless implantable microchip drug delivery technology) in a stock transaction with the potential for earn-outs.

Digital Transformation: A Guide for Pharma Marketers
Published: 21 Nov 2019 | 0:00 UTC

Artificial intelligence (AI) and machine learning (ML) are not yet perfect sciences, but they are transforming life sciences companies in practical and meaningful ways. This includes improving targeting and relationships with healthcare providers (HCPs) and patients. However, organization

Carlsmed Appoints New Chief Operating Officer
Published: 20 Nov 2019 | 18:46 UTC

The company uses AI and predictive analytics to fit spinal deformity treatments to individual patients.

Antares, Idorsia team up to develop drug-device combo product for myocardial infarction
Published: 20 Nov 2019 | 5:40 UTC

Idorsia Pharmaceuticals Ltd. and Antares Pharma Inc. are teaming up to develop a drug-device product that delivers Idorsia’s selatogrel using Antares’ subcutaneous QuickShot auto-injector for adults with suspected acute myocardial infarction (AMI).

ICU Medical buys HD catheter infection-prevention device firm Pursuit Vascular for up to $125mm
Published: 20 Nov 2019 | 5:40 UTC

ICU Medical Inc. agreed to acquire privately held Pursuit Vascular Inc. (device to reduce catheter-related bloodstream infections (CRBSIs) in hemodialysis (HD) patients).

Exagen completes $53.9mm IPO, five years after first filing
Published: 19 Nov 2019 | 17:29 UTC

Exagen Diagnostics Inc. (autoimmune disease testing and therapeutic drug monitoring) netted $53.9mm through its initial public offering of 4.14mm common shares (including the overallotment) at $14. The company first filed for an IPO back in 2014, but never completed the process.

Sera Prognostics closes $36mm Series D round
Published: 15 Nov 2019 | 5:40 UTC

Sera Prognostics Inc. (proteomics tests for the early prediction of preterm birth defects and other pregnancy-related complications) closed a $36mm Series D round co-led by new investor Blue Ox Healthcare and two undisclosed healthcare companies. Returning backers Domain Associates, InterWest Partners, Laboratory Corp. of America Holdings, Catalyst Health Ventures, and Chione Ltd. also participated. The company will use the proceeds to expand commercialization of and improve its clinically validated PreTRM, a biomarker blood test that assesses individualized risk of premature delivery. Since its 2008 inception, Sera has raised $122mm.

A Meaningful Customer-Centric Digital Strategy
Published: 8 Nov 2019 | 0:00 UTC

Data is fast becoming the most valuable commodity known to man. As an infinite resource with evolving applications, the pace at which organizations can acquire, manage the flow of, and leverage data is becoming a crucial factor in the future success of businesses, write Pamela Walk

Stryker buys Wright Medical Group; enterprise value of $5.4bn
Published: 7 Nov 2019 | 5:40 UTC

Stryker Corp. is paying $30.75 per share (a 50% premium) or $4.7bn to acquire fellow public orthopedics firm Wright Medical Group NV. The deal has a total enterprise value of about $5.4bn (including convertible notes).

Siemens Healthineers’ $1.1 Billion Buyout of Corindus Goes Through
Published: 29 Oct 2019 | 16:18 UTC

Corindus’ robotics system lets physicians accurately control guide catheters, guide wires, balloon implants and stent implants through the use of integrated imaging

Bausch & Lomb gets US and Canadian rights to Clearside's Xipere
Published: 26 Oct 2019 | 3:40 UTC

Clearside Biomedical Inc. licensed Bausch & Lomb Inc. exclusive rights to develop, manufacture, and commercialize Xipere (triamcinolone acetonide) suprachoroidal injectable suspension for macular edema and uveitis in the US and Canada.

Bryn licenses exclusive global rights to Aptar's bidose nasal delivery device
Published: 26 Oct 2019 | 3:40 UTC

Bryn Pharma LLC licensed exclusive global rights to use Aptar Pharma’s bidose (BDS) nasal device to deliver its epinephrine nasal spray BRYN-NDS1C.

FDA Task Force Supports Rating System for Drug Shortages, Woodcock Says
Published: 25 Oct 2019 | 22:54 UTC

CDER Director Janet Woodcock said an agency task force supports a new rating system designed to inform purchasers about drug facilities with higher reliability.

Opko, BMS aim to develop Alzheimer’s blood test
Published: 23 Oct 2019 | 3:40 UTC

Opko Health Inc. (point-of-care and molecular diagnostics and vaccines) and Bristol-Myers Squibb Co. will nonexclusively collaborate on the further development of Opko’s Alzheimer’s disease blood test.

Bryn to Use Aptar Pharma’s Nasal Device for Epinephrine Delivery
Published: 22 Oct 2019 | 19:05 UTC

"We are excited to partner with Aptar Pharma to develop a product that can provide patients with a life-saving treatment,” said Bryn Pharma CEO David Dworaczyk.

CellaVision pays SEK268mm for RAL Diagnostics
Published: 12 Oct 2019 | 3:40 UTC

CellaVision AB acquired privately held cellular imaging company RAL Diagnostics for SEK268mm ($29.8mm).

Takeda and Prometheus Biosciences enter IBD partnership
Published: 9 Oct 2019 | 3:40 UTC

Takeda Pharmaceutical Co. Ltd. penned an agreement with Prometheus Biosciences Inc. (formerly Precision IBD) for the discovery and development of up to three new therapies (and related companion diagnostics) for inflammatory bowel disease (IBD).

NeuCyte licenses Trillium's epilepsy candidate
Published: 28 Sep 2019 | 3:40 UTC

NeuCyte Inc. licensed exclusive worldwide development and commercialization rights to Trillium Therapeutics Inc.'s undisclosed refractory epilepsy compound for Dravet syndrome and related disorders.

More batches of common hypertension drug taken off the market
Published: 27 Sep 2019 | 11:00 UTC

Torrent Pharmaceuticals Ltd. is withdrawing more batches of Losartan potassium tablets, USP and Losartan potassium/hydrochlorothiazide tablets, USP.

Value-Based Agency Contracting Clears a Path to Better Outcomes for All
Published: 16 Sep 2019 | 0:00 UTC

Kevin Troyanos Between 2015 and 2017, growth in not-for profit hospitals expenses outpaced growth in their revenues by a full three percentage points, 1 resulting in a collective $6.8 billion of lost earnings. Thanks in no small part to their affiliated hospitals financial struggle

Curetis, OpGen merge
Published: 6 Sep 2019 | 3:40 UTC

Curetis NV and fellow public infectious disease-focused molecular diagnostics firm OpGen Inc. are reverse merging.

Exact Sciences and Genomic Health merge in $2.8bn deal
Published: 31 Jul 2019 | 3:41 UTC

Exact Sciences Corp. and Genomic Health Inc. have agreed to merge in a $2.8bn deal that would create a leading global molecular diagnostics company.

New drug relieves acute migraine in clinical trial
Published: 12 Jul 2019 | 16:00 UTC

The results of a large phase III trial show that the novel drug rimegepant can relieve pain and other symptoms of acute migraine with minimal side effects.

Switching off this enzyme reversed prediabetes in mice
Published: 9 Jul 2019 | 17:00 UTC

A new study shows that deactivating an enzyme that alters ceramides can prevent insulin resistance and fatty liver as well as reverse prediabetes in mice.



Please note that GR Consulting can not alter or influence the messages displayed, nor is it responsible for its content. If needed or desired, please refer to the original message and/or its originator.